cytarabine has been researched along with cyclosporine in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (26.09) | 18.2507 |
| 2000's | 31 (44.93) | 29.6817 |
| 2010's | 20 (28.99) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Antoniadis, A; Christodoulou, D; Dimitriadou, A; Exindari, M; Haitoglou, K; Malissiovas, N; Trakatellis, A | 1 |
| Anzai, S; Fujimaki, K; Fujisawa, S; Fukawa, H; Hattori, M; Motomura, S; Okubo, T | 1 |
| Baruchel, A; Devergie, A; Esperou Bourdeau, H; Hirsch, I; Moussalem, M; Parquet, N; Ribaud, P; Schaison, G; Socie, G; Traineau, R | 1 |
| Hussein, AM; Peters, WP; Stuart, A | 1 |
| Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R | 1 |
| Attal, M; Brousset, P; Dastugue, N; Demur, C; Duchayne, E; Rigal-Huguet, F; Robert, A; Rubie, H | 1 |
| Abella, E; de Planque, MM; Eisenbrey, AB; Karanes, C; Lum, LG; Ratanatharathorn, V; Ravindranath, Y; Schultz, KR; Sensenbrenner, LL; Uberti, JP | 1 |
| Choudhury, S; Hait, WN; Murren, JR; Srimatkandada, S | 1 |
| Jelkmann, W; Wolff, M | 1 |
| Friedman, AW; McCune, WJ | 1 |
| Estey, EH; Simon, RM; Thall, PF | 1 |
| Burke, M; Crawford, DH; Hunt, BJ; Thomas, JA; Walker, H; Yacoub, M | 1 |
| Openshaw, H | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Asano, S; Kikuchi, A; Nishikawa, T; Okamoto, S; Takahashi, S | 1 |
| Baccarani, M; Baraldo, M; Damiani, D; Ermacora, A; Fanin, R; Furlanut, M; Michieli, M; Pea, F; Russo, D; Zaja, F | 1 |
| Jabłoński, M; Machaczka, M; Rucińska, M; Skotnicki, AB | 1 |
| Bennett, JM; Lee, S; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS; Wiernik, PH | 1 |
| Benz, MS; Kramer, D; Murray, TG; Scott, IU; Toledano, S | 1 |
| Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H | 1 |
| Akasya, E; Büyükbabani, N; Diz-Küçükkaya, R; Oncü, S; Ozkaya-Bayazit, E; Pekçelen, Y | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Burnett, AK; Liu Yin, JA; Rees, JK; Wheatley, K | 1 |
| Albertioni, F; Eriksson, S; Löfgren, C; Månsson, E; Paul, A; Paul, C; Ullberg, K | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Appelbaum, FR; Doroshow, JH; Dorr, R; Head, DR; Hynes, HE; Karanes, C; Kopecky, KJ; List, AF; Persons, DL; Shurafa, M; Slovak, ML; Willman, CL | 1 |
| Ait Arkoub, Z; Arnulf, B; Chebbi, F; Fillet, AM; Lefrere, F; Varet, B | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Appelbaum, FR | 1 |
| Barbui, T; Bassan, R; Borleri, G; Buelli, M; Chiodini, B; Lerede, T; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Baker, KS; Nagarajan, R; Neglia, J; Ramsay, N | 1 |
| Ikeda, Y; Matsuzaki, M; Sakemi, T; Sano, M | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Deschênes, G; Landman-Parker, J; Lucidarme, N; Nathanson, S | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Aoki, Y; Ishizaki, J; Miyamoto, K; Nishigami, J; Nomura, M; Shimada, T; Yokogawa, K | 1 |
| Apostolidou, E; Cortes, J; Estey, E; Giles, FJ; Kantarjian, H; Tsimberidou, A | 1 |
| Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A; Verstovsek, S | 1 |
| Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, S; Thomas, DA; Tsimberidou, AM; Verstovsek, S | 1 |
| Takeshita, A | 1 |
| Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
| Bader, P; Boppana, S; Dormann, S; Fisch, P; Goebel, H; Jung, A; Kontny, U; Niemeyer, C; Peters, A; Strahm, B; Werner, M | 1 |
| Apostolidis, I; Arvanitopoulou, E; Asprogeraka, T; Bakiri, M; Giannakoulas, N; Kotsianidis, I; Marinakis, T; Matsouka, P; Pagoni, M; Papaioannou, M; Skandali, A; Spanoudakis, E; Tsatalas, K; Viniou, N; Yataganas, X; Zikos, P | 1 |
| Assanasen, T; Intragumtornchai, T; Nakorn, TN; Rojnuckarin, P; Wannakrairot, P | 1 |
| Chiba, S; Izutsu, K; Kako, S; Kanda, Y; Kurokawa, M; Motokura, T; Oshima, K; Sato, H | 1 |
| Avcu, F; Baran, Y; Gündüz, U; Gür, B; Kaya, P; Ural, AU | 1 |
| Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B | 1 |
| Behr, S; Llabrés-Días, FJ; Radaelli, ST | 1 |
| Appelbaum, FR; Chauncey, TR; Chen, IM; Dakhil, SR; Erba, HP; Gundacker, H; Kopecky, KJ; List, AF; Shadman, M; Slovak, ML; Willman, CL | 1 |
| Aghakhani, R; Alavi, S; Arzanian, MT; Gharib, A; Goudarzipour, K; Jadali, F; Rezaei, N; Shamsian, BS | 1 |
| Babyn, P; Chan, HS; Dimaras, H; Doyle, J; Gallie, BL; Halliday, W; Héon, E; Paton, KE; Strahlendorf, C | 1 |
| Beutel, G; Buchholz, S; Dammann, E; Eder, M; Ganser, A; Krauter, J; Stadler, M; Trummer, A | 1 |
| Berkowitz, J; Bernard, L; Hogge, DE; Kim, HP; Nitta, J | 1 |
| Fujisawa, S; Fujita, H; Kanamori, H; Kanda, Y; Kobayashi, T; Mori, T; Nakaseko, C; Nannya, Y; Ohashi, K; Okamoto, S; Sakamaki, H; Sakura, T; Takahashi, S; Tanaka, M; Yokota, A | 1 |
| Beato Merino, MJ; Gómez-Fernández, C; Hernández-Maraver, D; Herranz Pinto, P; Maldonado Cid, P; Noguera Morel, L; Sendagorta Cudós, E | 1 |
| de Vries, R; van de Merbel, NC | 1 |
| Tohyama, K | 1 |
| Chen, CC; Teng, CL; Yeh, SP | 1 |
| Bessho, F; Fujimoto, J; Horibe, K; Imamura, T; Imashuku, S; Ishii, E; Kawaguchi, H; Kobayashi, R; Koga, Y; Kudo, K; Morimoto, A; Sakashita, K; Shioda, Y; Tsunematsu, Y; Yasui, M | 1 |
| Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bhatti, SFM; Cornelis, I; De Decker, S; Gielen, I; Van Ham, L | 1 |
| Cardarelli, L; Chiaretti, S; Diverio, D; Foà, R; Giona, F; Mancini, F; Miano, M; Moleti, ML; Nanni, M; Palumbo, G; Peragine, N; Santopietro, M; Testi, AM; Zhang, K | 1 |
10 review(s) available for cytarabine and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Immunosuppressive drug therapy for rheumatic disease.
Topics: Cyclophosphamide; Cyclosporine; Cytarabine; Humans; Immunosuppressive Agents; Rheumatic Diseases | 1993 |
Peripheral neuropathy after bone marrow transplantation.
Topics: Bone Marrow Transplantation; Cyclosporine; Cytarabine; Demyelinating Diseases; Humans; Immunosuppressive Agents; Interferon-alpha; Peripheral Nervous System Diseases; Tacrolimus; Time Factors | 1997 |
[The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cyclosporine; Cyclosporins; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Middle Aged; Survival Rate | 1998 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation.
Topics: Bone Marrow; Cladribine; Combined Modality Therapy; Cyclosporine; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant, Newborn; Mercaptopurine; Methotrexate; Methylprednisolone; Prednisone; Remission Induction; Transplantation, Homologous; Vinblastine | 2001 |
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil | 2003 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclosporine; Cytarabine; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Cutaneous; Male; Methylprednisolone; Multimodal Imaging; Panniculitis; Positron-Emission Tomography; Recurrence; Remission Induction; Salvage Therapy; Skin Neoplasms; Subcutaneous Fat; Tomography, X-Ray Computed | 2016 |
Clinical presentation, diagnostic findings, prognostic factors, treatment and outcome in dogs with meningoencephalomyelitis of unknown origin: A review.
Topics: Animals; Cyclosporine; Cytarabine; Dog Diseases; Dogs; Immunosuppressive Agents; Magnetic Resonance Imaging; Meningoencephalitis; Prednisolone; Prognosis; Treatment Outcome | 2019 |
14 trial(s) available for cytarabine and cyclosporine
| Article | Year |
|---|---|
Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
Topics: Anemia, Refractory; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Methotrexate; Myelodysplastic Syndromes; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chemotherapy, Adjuvant; Creatinine; Cyclosporine; Cytarabine; Feasibility Studies; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome | 1998 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 2001 |
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk Factors | 2001 |
Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Treatment Outcome | 2002 |
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine | 2003 |
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Daunorubicin; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Pilot Projects; Remission Induction; Salvage Therapy; Treatment Outcome | 2003 |
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Platelet Count; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Vidarabine | 2003 |
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Greece; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Societies, Medical; Survival Analysis; Treatment Outcome | 2006 |
Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Cyclosporine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Dyes; Humans; Idarubicin; Inhibitory Concentration 50; K562 Cells; Leukemia, Myeloid, Acute; Male; Rhodamine 123; Time Factors; Treatment Outcome; Verapamil | 2009 |
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epidemiologic Methods; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Treatment Outcome | 2010 |
Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycophenolic Acid; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies.
Topics: Adult; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Prospective Studies; Risk; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Whole-Body Irradiation | 2013 |
45 other study(ies) available for cytarabine and cyclosporine
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of combination of deoxypyridoxine with known anti-proliferative or immunosuppressive agents on lymphocyte serine hydroxymethyltransferase.
Topics: Antineoplastic Agents; Asparaginase; Cells, Cultured; Cyclosporine; Cytarabine; Dactinomycin; Glycine Hydroxymethyltransferase; Humans; Immunosuppressive Agents; Lymphocytes; Pyridoxine | 1994 |
[Intermittent-dose ara-C/daunomycin therapy combined with cyclosporin-A and G-CSF led to a fourth remission in a patient with acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Recurrence; Remission Induction | 1995 |
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cause of Death; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Male; Melphalan; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Whole-Body Irradiation | 1995 |
Protection against chemotherapy-induced alopecia by cyclosporin A in the newborn rat animal model.
Topics: Administration, Cutaneous; Alopecia; Animals; Animals, Newborn; Antineoplastic Agents; Cyclophosphamide; Cyclosporine; Cytarabine; Disease Models, Animal; Etoposide; Injections, Intraperitoneal; Rats; Rats, Sprague-Dawley | 1995 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Leukemia; Lung Diseases, Interstitial; Male; Methylprednisolone; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Tissue Donors; Treatment Outcome; Whole-Body Irradiation; Wisconsin | 1995 |
Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Tissue Donors | 1994 |
Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Southern; Cell Differentiation; Cyclosporine; Cytarabine; DNA; Drug Resistance; Flupenthixol; Gene Expression; Hemin; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; RNA, Messenger; Transfection; Tumor Cells, Cultured; Vinblastine | 1993 |
Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures.
Topics: Animals; Antineoplastic Agents; Azathioprine; Colchicine; Cyclophosphamide; Cyclosporine; Cytarabine; Daunorubicin; Erythropoietin; Humans; Ifosfamide; Immunosuppressive Agents; L-Lactate Dehydrogenase; Liver Neoplasms, Experimental; Methotrexate; Organoplatinum Compounds; Tetrazolium Salts; Tumor Cells, Cultured; Vincristine | 1993 |
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cyclosporine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mathematical Computing; Monitoring, Physiologic; Probability; Remission Induction; Research Design | 1996 |
Epstein-Barr virus associated Burkitt lymphoma in a heart transplant recipient.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide; Cyclosporine; Cytarabine; Doxorubicin; Etoposide; Heart Transplantation; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Postoperative Complications; Prednisolone; Remission Induction; T-Lymphocytes, Cytotoxic; Tumor Virus Infections; Vincristine | 1996 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Linear chronic cutaneous graft-versus-host disease.
Topics: Adult; Basement Membrane; Bone Marrow Transplantation; Chronic Disease; Cyclosporine; Cytarabine; E-Selectin; Epidermis; Graft vs Host Disease; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Keratosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Methotrexate; Platelet Endothelial Cell Adhesion Molecule-1; Transplantation, Homologous; Whole-Body Irradiation | 1997 |
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukemia, Myeloid; Leukopenia; Liver; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1999 |
Complications of systemic chemotherapy as treatment of retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclosporine; Cytarabine; Etoposide; Female; Fever; Humans; Infant; Male; Methotrexate; Neutropenia; Organophosphorus Compounds; Retinal Neoplasms; Retinoblastoma; Thrombocytopenia; Vincristine | 2000 |
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Homologous | 2000 |
Bullous acral erythema and concomitant pigmentation on the face and occluded skin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Daunorubicin; Drug Eruptions; Erythema; Female; Hand Dermatoses; Humans; Hyperpigmentation; Leukemia, Myeloid; Skin Diseases, Vesiculobullous | 2000 |
Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cyclosporins; Cytarabine; Deoxycytidine Kinase; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Flow Cytometry; Fluoresceins; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute | 2001 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Combined Modality Therapy; Cyclosporine; Cytarabine; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Fatal Outcome; Foscarnet; Graft vs Host Disease; Herpes Genitalis; Herpes Simplex; Humans; Hydroxyurea; Immunocompromised Host; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Simplexvirus; Transplantation Conditioning; Whole-Body Irradiation | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Hematopoietic cell transplantation beyond first remission.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Nuclear Family; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Acute myelogenous leukemia following treatment with cyclosporin A in a nephrotic patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclosporine; Cytarabine; Daunorubicin; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Nephrotic Syndrome; Treatment Outcome | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Long-term survival of renal graft complicated with Burkitt lymphoma.
Topics: Antimetabolites, Antineoplastic; Burkitt Lymphoma; Creatinine; Cyclosporine; Cytarabine; Graft Survival; Humans; Immunosuppressive Agents; Infant; Kidney Neoplasms; Kidney Transplantation; Liver Neoplasms; Male; Nephrotic Syndrome; Splenic Neoplasms | 2002 |
Influence of cytarabine and cyclophosphamide on the disposition kinetics of cyclosporin A after bone marrow transplantation.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Blotting, Western; Bone Marrow Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Cytochrome P-450 CYP3A; Immunosuppressive Agents; Liver; Male; Membrane Proteins; Osmolar Concentration; Postoperative Period; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2003 |
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine | 2003 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Clone Cells; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Cytarabine; Daunorubicin; Dexamethasone; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Glucocorticoids; Graft vs Host Disease; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Leukemia-Lymphoma, Adult T-Cell; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Postoperative Complications; Prednisolone; Rituximab; Time Factors; Transplantation Chimera; Transplantation Conditioning; Vincristine; Virus Activation; Whole-Body Irradiation | 2005 |
Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cyclosporine; Cytarabine; Doxorubicin; Etoposide; Female; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Cutaneous; Male; Methylprednisolone; Middle Aged; Panniculitis; Prednisone; Prognosis; Remission Induction; Skin Neoplasms; Treatment Outcome; Vincristine | 2007 |
Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cryptogenic Organizing Pneumonia; Cyclophosphamide; Cyclosporine; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Methotrexate; Neoplasm Recurrence, Local; Palatal Neoplasms; Remission Induction; Salvage Therapy; Transplantation, Homologous; Vincristine | 2007 |
Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Therapy, Combination; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Lewis X Antigen; Multidrug Resistance-Associated Proteins; Receptors, IgG; Up-Regulation | 2007 |
Treatment of meningoencephalitis of unknown origin in a dog.
Topics: Animals; Anti-Inflammatory Agents; Cyclosporine; Cytarabine; Dog Diseases; Dogs; Immunosuppressive Agents; Male; Meningoencephalitis; Prednisolone; Treatment Outcome | 2009 |
Langerhans cell histiocytosis in a child with non-Hodgkin lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporine; Cytarabine; Female; Histiocytosis, Langerhans-Cell; Humans; Lymphoma, Non-Hodgkin; Mercaptopurine; Methotrexate; Prednisolone; Prednisone; Vinblastine; Vincristine | 2010 |
Multifaceted chemotherapy for trilateral retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cyclosporine; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Pineal Gland; Retinal Neoplasms; Retinoblastoma; Tomography, X-Ray Computed; Topotecan; Vincristine | 2011 |
Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cyclosporine; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Induction Chemotherapy; Karyotype; Leukemia, Myeloid, Acute; Lymphoid Progenitor Cells; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Statistics, Nonparametric; Young Adult | 2012 |
Acral erythema worsened by intravenous infusions of cyclosporin.
Topics: Adult; Antineoplastic Agents; Cyclosporine; Cytarabine; Drug Eruptions; Erythema; Graft vs Host Disease; Humans; Infusions, Intravenous; Male; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2013 |
Aging of biological matrices and its effect on bioanalytical method performance.
Topics: Animals; Cholesterol; Chromatography, High Pressure Liquid; Cyclosporine; Cytarabine; Humans; Hydroxycholesterols; Isotope Labeling; Mice; Oxidation-Reduction; Serum; Spectrometry, Mass, Electrospray Ionization; Temperature; Time Factors; Ubiquinone | 2013 |
Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Topics: Adolescent; Child; Child, Preschool; Clinical Protocols; Cyclosporine; Cytarabine; Disease-Free Survival; Drug Therapy, Combination; Histiocytosis, Langerhans-Cell; Humans; Multiple Organ Failure; Prednisolone; Remission Induction; Time Factors; Treatment Outcome; Vincristine | 2016 |
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia.
Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Etoposide; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Prednisolone; Pyridazines | 2019 |